Upcoming Events
Log In
Pricing
Free Trial

Donanemab

HIDE
PrevNext

0:01

Now in the Trailblazer Alls two phase three trial,

0:03

which was published in JAMA on uh, July 17th, 2023,

0:07

so just published, umab met the primary efficacy endpoint

0:10

by slowing the rate of cognitive decline

0:12

by 35% at 18 months.

0:14

Additionally, nearly half. So 47%

0:16

of the UMAB participants had no disease progression at one

0:21

year, uh, with the CDR SB rating scale.

0:24

So that is a really big deal.

0:26

Um, patients with less advanced disease, so patients

0:29

that had lower medium tau burden outperform those

0:32

with more advanced disease that had higher tau burden.

0:34

And that is just confirming that,

0:36

that earlier the treatment is initiated,

0:38

the higher the clinical benefit, uh, which is why the, um,

0:42

the labels are suggesting this at the early stages

0:45

of disease.

Report

Faculty

Suzie Bash, MD

Medical Director of Neuroradiology

San Fernando Valley Interventional Radiology & Imaging (SFI), RadNet

Tags

Neuroradiology

MRI

Iatrogenic

Brain